文献速递肝病

奥贝胆酸治疗原发性硬化性胆管炎的随机安慰剂对照II期研究

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
PubMed 文献 · J Hepatol · 2020-03-10

AESOP研究为II期随机双盲安慰剂对照剂量探索试验,纳入76例原发性硬化性胆管炎(PSC)患者,随机接受安慰剂、奥贝胆酸(OCA)1.5-3.0 mg或5-10 mg治疗24周。主要终点为碱性磷酸酶(ALP)自基线变化及安全性。结果显示OCA 5-10 mg组ALP较安慰剂显著降低,最常见不良事件为剂量相关瘙痒。

要点

  • OCA 5-10 mg治疗24周可显著降低PSC患者血清ALP水平
  • OCA 1.5-3.0 mg组ALP降低未达统计学显著
  • 剂量相关瘙痒为最常见不良事件,长期扩展期未现新安全信号

核心结论

  • OCA 5-10 mg可降低PSC患者血清ALP,且疗效在2年长期扩展期中维持。

研究设计与样本

  • AESOP为II期随机双盲安慰剂对照剂量探索研究,纳入18-75岁PSC患者,随机1:1:1接受安慰剂、OCA 1.5-3.0 mg或5-10 mg每日一次。
  • 意向治疗人群共76例:安慰剂组25例,OCA 1.5-3.0 mg组25例,OCA 5-10 mg组26例。
  • 治疗24周双盲期后进入2年长期安全性扩展期。

主要发现

  • 第24周时,OCA 5-10 mg组血清ALP较安慰剂显著降低(最小二乘均值差=-83.4 U/L,SE=40.3,95%CI -164.28至-2.57,p=0.043)。
  • OCA 1.5-3.0 mg组第24周ALP较安慰剂降低未达统计学显著(最小二乘均值差=-78.29 U/L,SE=41.81,95%CI -162.08至5.50,p=0.067)。
  • 所有组总胆红素与基线相当。
  • 最常见治疗中出现的不良事件为剂量相关瘙痒:安慰剂组46%,OCA 1.5-3.0 mg组60%,OCA 5-10 mg组67%。
  • 长期扩展期中ALP降低得以维持,未出现新安全信号。

关键数值与推荐

  • 纳入标准:诊断为PSC,血清ALP≥2倍正常值上限(ULN),总胆红素<2.5倍ULN。
  • 主要终点:第24周ALP自基线变化及安全性。

临床怎么用

  • OCA 5-10 mg可能作为PSC患者降低ALP的治疗选择,但需关注剂量相关瘙痒。
  • OCA 1.5-3.0 mg剂量在本研究中未显示显著ALP降低效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a rare, cholestatic liver disease with no currently approved therapies. Obeticholic acid (OCA) is a potent farnesoid X receptor (FXR) agonist approved for the treatment of primary biliary cholangitis. We investigated the efficacy and safety of OCA in patients with PSC. METHODS: AESOP was a phase II, randomized, double-blind, placebo-controlled, dose-finding study. Eligible patients were 18 to 75 years of age with a diagnosis of PSC and serum alkaline phosphatase (ALP) ≥2× the upper limit of normal (ULN) and total bilirubin <2.5× ULN. Patients were randomized 1:1:1 to receive placebo, OCA 1.5-3.0 mg, or OCA 5-10 mg once daily for a 24-week, double-blind phase followed by a 2-year, long-term safety extension (LTSE). Primary endpoints were change in ALP from baseline to week 24, and safety. RESULTS: The intent-to-treat population comprised 76 patients randomized to placebo (n = 25), OCA 1.5-3.0 mg (n = 25), and OCA 5-10 mg (n = 26). At week 24, serum ALP was significantly reduced with OCA 5-10 mg vs. placebo (least-square [LS] mean difference = -83.4 [SE = 40.3] U/L; 95% CI -164.28 to -2.57; p = 0.043). Serum ALP was not significantly reduced with OCA 1.5-3.0 mg vs. placebo at week 24 (LS mean [SE] difference = -78.29 [41.81] U/L; 95% CI -162.08 to 5.50; p = 0.067). Total bilirubin remained comparable to baseline in all groups. The most common treatment-emergent adverse event was dose-related pruritus (placebo 46%; OCA 1.5-3.0 mg 60%; OCA 5-10 mg 67%). Reductions in ALP were maintained during the LTSE, and no new safety signals emerged. CONCLUSIONS: Treatment with OCA 5-10 mg reduced serum ALP in patients with PSC. Mild to moderate dose-related pruritus was the most common adverse event. REGISTRATION: ClinicalTrials.gov: NCT02177136; EudraCT: 2014-002205-38. LAY SUMMARY: Primary sclerosing cholangitis (PSC) is a long-term disease that damages the bile ducts in the liver over time. In the AESOP clinical study in patients with PSC, obeticholic acid reduced serum alkaline phosphatase (a potential marker of disease severity) during an initial 24-week treatment period. The result was sustained during the 2-year, long-term extension of the study. The most common side effect of obeticholic acid in the study was itchy skin, which is consistent with earlier clinical studies.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kowdley KV, Vuppalanchi R, Levy C, et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol. 2020. PMID: 32165251. doi:10.1016/j.jhep.2020.02.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。